Guj. Themis Bio.

What is the bonus history of the Guj. Themis Bio.?

Gujarat Themis Biosyn Ltd announced a 1:2 bonus issue, with an ex-date of August 9, 2024, meaning shareholders will receive 1 additional share for every 2 shares held.

Gujarat Themis Biosyn Ltd has a recent bonus issue history where they announced a 1:2 bonus. The ex-date for this bonus is set for August 9, 2024. This means that for every 2 shares held, shareholders will receive 1 additional share. If you need further details or have more questions about the company, feel free to ask!

Has Guj. Themis Bio. declared dividend?

Gujarat Themis Biosyn Ltd has declared a 25% dividend, amounting to ₹0.25 per share, with an ex-date of July 15, 2024. The company has shown strong total returns over various periods, particularly impressive over the long term, despite recent fluctuations.

Gujarat Themis Biosyn Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.25<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.51%, the dividend return was 0%, resulting in a total return of -4.51%.<BR><BR>Over the past year, the price return was 24.43%, the dividend return was 0.09%, leading to a total return of 24.52%.<BR><BR>In the two-year period, the price return was 215.74%, the dividend return was 1.90%, culminating in a total return of 217.64%.<BR><BR>For the three-year period, the price return was 477.99%, the dividend return was 19.37%, resulting in a total return of 497.36%.<BR><BR>In the four-year span, the price return was 768.42%, the dividend return was 36.29%, which led to a total return of 804.71%.<BR><BR>Over the last five years, the price return was 1327.87%, the dividend return was 64.80%, resulting in a total return of 1392.67%.<BR><BR>Overall, Gujarat Themis Biosyn Ltd has declared a dividend while also showing significant total returns over various periods, particularly impressive over the longer term, indicating strong performance despite recent fluctuations.

Who are the peers of the Guj. Themis Bio.?

Guj. Themis Bio.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, Panacea Biotec, IOL Chemicals, Novartis India, and Zota Health Care. Guj. Themis Bio. has average growth and management risk, with a 1-year return of 22.35%, higher than Orchid Pharma but lower than Panacea Biotec's 269.46%.

Peers: The peers of Guj. Themis Bio. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, Panacea Biotec, IOL Chemicals, Novartis India, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Guj. Themis Bio., while Average management risk is found at IOL Chemicals and Novartis India, and Below Average management risk is noted at Orchid Pharma, Panacea Biotec, and Zota Health Care. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Guj. Themis Bio., Orchid Pharma, Panacea Biotec, and Zota Health Care, with Average growth at IOL Chemicals and Good growth at Novartis India. Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Guj. Themis Bio., IOL Chemicals, and Novartis India, while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Orchid Pharma, Panacea Biotec, and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while the peer with the lowest is Orchid Pharma at -31.48%. Guj. Themis Bio.'s 1-year return of 22.35% is significantly higher than Orchid Pharma's but lower than Panacea Biotec's. Additionally, Orchid Pharma and Zota Health Care have negative six-month returns.

Is Guj. Themis Bio. overvalued or undervalued?

As of May 5, 2021, Guj. Themis Bio. is considered very expensive and overvalued with a PE Ratio of 72.45 and an EV to EBITDA of 51.24, significantly higher than competitors like Sun Pharma and Cipla, despite its impressive returns over the past three years.

As of 5 May 2021, the valuation grade for Guj. Themis Bio. moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently deemed overvalued. Key ratios include a PE Ratio of 72.45, an EV to EBITDA of 51.24, and a Price to Book Value of 15.82, all of which are substantially higher than industry peers. <BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE Ratio of 22.99 and an EV to EBITDA of 15.93, highlighting that Guj. Themis Bio. is trading at a premium relative to these competitors. Additionally, despite its high returns over various periods, including a 511.99% return over three years compared to the Sensex's 49.20%, the elevated valuation metrics suggest that the stock may not be justified at its current price level.

Who are in the management team of Guj. Themis Bio.?

As of March 2023, the management team of Guj. Themis Bio. includes Dinesh S Patel (Chairman), Sachin D Patel, and four independent non-executive directors: Vijay Gopi Kishan Agarwal, Kirandeep Madan, Vikram D Sanghvi, and Siddharth Y Kusumgar.

As of March 2023, the management team of Guj. Themis Bio. includes the following individuals:<BR><BR>1. Dinesh S Patel - Chairman & Non Executive Director<BR>2. Sachin D Patel - Non Executive Director<BR>3. Vijay Gopi Kishan Agarwal - Independent Non Executive Director<BR>4. Kirandeep Madan - Independent Non Executive Director<BR>5. Vikram D Sanghvi - Independent Non Executive Director<BR>6. Siddharth Y Kusumgar - Independent Non Executive Director<BR><BR>These members play various roles within the company's board of directors.

What does Guj. Themis Bio. do?

Gujarat Themis Biosyn Ltd is a small-cap pharmaceutical and biotechnology company, incorporated in 1981 and currently owned by the Yuhan Group. As of March 2025, it reported net sales of ₹377 Cr and a net profit of ₹120 Cr, with a market cap of ₹4,045 Cr.

Overview: <BR>Gujarat Themis Biosyn Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>The company was incorporated in 1981 and underwent a significant change in ownership in June 1991 when it was taken over by the Yuhan Group from South Korea and Pharmaceutical Business Group (India) Ltd. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 377 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 120 Cr (Quarterly Results - Mar 2025) <BR>Market cap: INR 4,045 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 83.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.05% <BR>Debt Equity: -0.03 <BR>Return on Equity: 21.83% <BR>Price to Book: 17.52 <BR><BR>Contact Details: <BR>Address: 69/C GIDC Industrial Estate, Valsad Dist VAPI Gujarat : 396195 <BR>Tel: 91-260-2430027 <BR>Email: accounts@gtbl.co.in/gtblmumbai@gtbl <BR>Website: http://www.gtbl.in

Who are the top shareholders of the Guj. Themis Bio.?

The top shareholders of Guj. Themis Bio include Pharmaceutical Business Group [India] Ltd with 47.02%, individual investors holding 19.31%, and foreign institutional investors at 2.51%. Additionally, mutual funds hold 1.16%, with Quant Mutual Fund - Quant Manufacturing Fund being the largest public shareholder at 1.15%.

The top shareholders of Guj. Themis Bio include the promoters, with the Pharmaceutical Business Group [India] Ltd holding the largest stake at 47.02%. Additionally, there are mutual funds involved, with five schemes collectively holding 1.16%, and foreign institutional investors (FIIs) holding 2.51% through ten different entities. The highest public shareholder is Quant Mutual Fund - Quant Manufacturing Fund, which has a holding of 1.15%. Individual investors also have a significant presence, owning 19.31% of the company.

How big is Guj. Themis Bio.?

As of 24th July, Gujarat Themis Biosyn Ltd has a market capitalization of 4,060.00 Cr, with Net Sales of 150.81 Cr and a Net Profit of 48.78 Cr for the latest four quarters. Shareholder's Funds are 201.38 Cr and Total Assets are 221.11 Cr as of March 2024.

As of 24th July, Gujarat Themis Biosyn Ltd has a market capitalization of 4,060.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 150.81 Cr and a Net Profit of 48.78 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 201.38 Cr and Total Assets of 221.11 Cr.

How has been the historical performance of Guj. Themis Bio.?

Guj. Themis Bio. experienced fluctuating net sales, reporting 150.80 Cr in Mar'25, down from 169.82 Cr in Mar'24 but up from 148.39 Cr in Mar'23. Profit metrics also declined, with profit after tax at 48.77 Cr in Mar'25, while total assets rose significantly to 301.31 Cr.

Answer:<BR>The historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years.<BR><BR>Breakdown:<BR>Guj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'25 from 221.11 Cr in Mar'24, driven by a rise in total reserves to 237.49 Cr. The company also saw an increase in long-term borrowings to 29.64 Cr in Mar'25, compared to none in the previous year. Cash flow from operating activities improved to 91.00 Cr in Mar'25, up from 64.00 Cr in Mar'24, contributing to a net cash inflow of 5.00 Cr in Mar'25.

Is Guj. Themis Bio. technically bullish or bearish?

As of November 20, 2025, the trend is mildly bullish due to positive weekly MACD and KST signals, though caution is warranted from a mildly bearish weekly Dow Theory and lack of momentum in the RSI.

As of 20 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly MACD and KST indicators showing bullish signals, while the daily moving averages also indicate a mildly bullish trend. However, the weekly Dow Theory is mildly bearish, which adds some caution. The RSI shows no signal on both weekly and monthly timeframes, suggesting a lack of momentum. Overall, the strength of the bullish stance is tempered by mixed signals from other indicators.

When is the next results date for Gujarat Themis Biosyn Ltd?

The next results date for Gujarat Themis Biosyn Ltd is February 5, 2026.

The next results date for Gujarat Themis Biosyn Ltd is scheduled for February 5, 2026.

Are Gujarat Themis Biosyn Ltd latest results good or bad?

Gujarat Themis Biosyn Ltd's latest Q3 FY26 results show strong sales growth at ₹43.37 crores, but a significant decline in net profit to ₹12.46 crores raises concerns about profitability and operational efficiency. Investors should be cautious as the company faces challenges in converting sales growth into profit.

Gujarat Themis Biosyn Ltd's latest results for Q3 FY26 present a mixed picture. On one hand, the company achieved its highest-ever quarterly sales of ₹43.37 crores, reflecting a growth of 2.41% quarter-on-quarter and 9.74% year-on-year. This indicates strong demand for its specialty pharmaceutical products.<BR><BR>However, the net profit has declined significantly, dropping to ₹12.46 crores, which is a decrease of 12.63% compared to the previous quarter and 3.93% year-on-year. This contraction in profit raises concerns about the company's operational efficiency and profitability margins, particularly as the PAT margin fell sharply to 28.73% from 33.67% in the previous quarter.<BR><BR>Overall, while the revenue growth is a positive sign, the decline in net profit and margins suggests that the company is facing challenges in translating its sales growth into bottom-line performance. Investors should be cautious and monitor how the company addresses these profitability issues moving forward.

Should I buy, sell or hold Gujarat Themis Biosyn Ltd?

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 17-Mar, Gujarat Themis Biosyn Ltd's stock price is at 275.00, reflecting a decline of -2.4 (-0.87%) and a total drop of -7.5% over the last three days. The stock is underperforming with significant declines over the past week and month, and is trading below all major moving averages, indicating a bearish trend.

As of 17-Mar, Gujarat Themis Biosyn Ltd's stock price is falling, currently at 275.00, reflecting a change of -2.4 (-0.87%). The stock has been underperforming, with a consecutive decline over the last three days, resulting in a total drop of -7.5% during this period. Additionally, the stock has shown significant negative performance over the past week and month, with declines of -8.12% and -13.07%, respectively.<BR><BR>Today's trading activity indicates that the stock touched an intraday high of Rs 288.85 but also reached a low of Rs 269.55, suggesting volatility within the trading session. The weighted average price indicates that more volume was traded closer to the low price, further emphasizing the downward trend. Moreover, Gujarat Themis Biosyn Ltd is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bearish trend.<BR><BR>Despite some positive factors, such as high management efficiency and a low debt-to-equity ratio, the company faces challenges that contribute to its falling stock price. Poor long-term growth is evident, with net sales growing at an annual rate of only 11.22% and operating profit at 7.23% over the last five years. Additionally, institutional investors have reduced their stake by -0.99% in the previous quarter, indicating a lack of confidence from larger investors. This decline in institutional participation, combined with flat financial results and a high valuation compared to peers, suggests that the stock's price is under pressure, leading to its current downward movement.

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 18-Mar, Gujarat Themis Biosyn Ltd's stock price is rising, currently at 283.65, reflecting an increase of 11.55 or 4.24%. The recent rise indicates a potential trend reversal after previous declines, supported by increased investor participation, although the stock still faces significant long-term challenges.

As of 18-Mar, Gujarat Themis Biosyn Ltd's stock price is rising, currently at 283.65, reflecting an increase of 11.55 or 4.24%. This upward movement comes after three consecutive days of decline, indicating a potential trend reversal. The stock opened with a gain of 2.22% today and reached an intraday high of Rs 287.6, which is a 5.7% increase. <BR><BR>Additionally, the stock has outperformed its sector by 3.97%, and there has been a notable rise in investor participation, with delivery volume increasing by 128.34% against the five-day average. This suggests a growing interest among investors, which is often a positive sign for stock price movements.<BR><BR>However, it is important to note that despite the current rise, the stock has experienced significant declines over longer periods, with a year-to-date drop of 35.89% and a one-month decrease of 17.65%. The stock is also trading below its moving averages across various time frames, indicating potential underlying weaknesses. <BR><BR>In summary, the recent rise in Gujarat Themis Biosyn Ltd's stock price is attributed to a short-term recovery after previous declines, increased investor participation, and positive performance relative to its sector, despite the backdrop of longer-term challenges.

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 19-Mar, Gujarat Themis Biosyn Ltd's stock price is at 274.80, down 3.46%, with a significant decline over the past week and month. The stock is underperforming its sector and shows a negative outlook due to reduced institutional investment and poor long-term growth metrics.

As of 19-Mar, Gujarat Themis Biosyn Ltd's stock price is falling, currently at 274.80, reflecting a decrease of 9.85 (-3.46%). The stock has underperformed the sector by 1.31% today and opened with a loss of 2.37%. It reached an intraday low of Rs 274.8, indicating a significant decline in value.<BR><BR>Over the past week, the stock has decreased by 7.57%, and in the last month, it has fallen by 16.04%, while year-to-date, it has dropped by 37.89%. This decline is contrasted by a modest annual increase of 8.21%, but it is important to note that profits have fallen by 9.3% during this period. The stock is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a consistent downward trend.<BR><BR>Additionally, the Pharmaceuticals & Drugs sector has seen a decline of 2.11%, which may be contributing to the stock's poor performance. There is also a noted decrease in participation from institutional investors, who have reduced their stake by 0.99% in the previous quarter, indicating a lack of confidence in the stock's future prospects. <BR><BR>Despite some positive factors, such as high management efficiency and a low debt-to-equity ratio, the overall outlook appears negative due to poor long-term growth metrics and high valuations compared to peers. These factors collectively contribute to the stock's current downward trajectory.

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 20-Mar, Gujarat Themis Biosyn Ltd's stock price is at 272.05, down 1.07%, and has underperformed its sector. The stock has declined significantly over the past month and year-to-date, with reduced investor participation and institutional stake, indicating a bearish trend and poor long-term growth outlook.

As of 20-Mar, Gujarat Themis Biosyn Ltd's stock price is falling, currently at 272.05, reflecting a decrease of 2.95 or 1.07%. The stock has underperformed its sector by 2.77% today and has experienced a consecutive decline over the last two days, with a total drop of 4.43% during this period. <BR><BR>In terms of performance metrics, the stock has shown a significant decline over the past month, down 18.82%, and a year-to-date drop of 38.51%, while the benchmark Sensex has only decreased by 12.54% in the same timeframe. Furthermore, the stock is trading below its moving averages across various timeframes, indicating a bearish trend. <BR><BR>Investor participation has also diminished, with delivery volume falling by 77.14% compared to the five-day average, suggesting a lack of interest among investors. Additionally, institutional investors have reduced their stake by 0.99% in the previous quarter, which may further contribute to the stock's downward pressure. <BR><BR>Despite some positive factors, such as high management efficiency and consistent returns over the last three years, the overall outlook is marred by poor long-term growth indicators, including low net sales growth and a high valuation compared to peers. These factors collectively explain the current decline in Gujarat Themis Biosyn Ltd's stock price.

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 23-Mar, Gujarat Themis Biosyn Ltd's stock price is at 258.80, down 5.93%, significantly underperforming its sector and showing a year-to-date decline of 41.51%. The stock's bearish trend is indicated by trading below moving averages and reduced investor participation, compounded by poor long-term growth prospects and high valuation concerns.

As of 23-Mar, Gujarat Themis Biosyn Ltd's stock price is falling, currently at 258.80, reflecting a decrease of 16.3 points or 5.93%. The stock has underperformed its sector, with a performance today that is 3.55% lower than the sector average. It opened the day with a loss of 3.16% and reached an intraday low of Rs 254.95, which is a significant drop of 7.32%. <BR><BR>Over the past week, the stock has declined by 6.71%, and in the last month, it has fallen by 22.68%, indicating a troubling trend. Year-to-date, the stock has decreased by 41.51%, while the Sensex has only dropped by 14.70%. This stark contrast highlights the stock's significant underperformance relative to the broader market.<BR><BR>The stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 69.52% compared to the 5-day average. This lack of interest from investors, particularly institutional investors who have reduced their stake by 0.99%, further contributes to the stock's downward pressure.<BR><BR>Despite some positive factors, such as high management efficiency and a low debt-to-equity ratio, the company faces challenges with poor long-term growth, as evidenced by net sales growth of only 11.22% and operating profit growth of 7.23% over the last five years. The company's valuation appears expensive compared to its peers, with a return on capital employed (ROCE) at a low 19.25%, which raises concerns among investors. Overall, these factors collectively explain the decline in Gujarat Themis Biosyn Ltd's stock price.

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 24-Mar, Gujarat Themis Biosyn Ltd's stock price is rising to 265.45, reflecting a short-term gain of 2.57%. However, the stock has a concerning long-term outlook with a year-to-date drop of 40% and declining investor interest.

As of 24-Mar, Gujarat Themis Biosyn Ltd's stock price is rising, currently at 265.45, reflecting a change of 6.65 (2.57%) upward. This increase can be attributed to several factors. Today, the stock opened with a gain of 2.4% and reached an intraday high of Rs 269.85, indicating positive momentum in the short term. Additionally, the stock has outperformed its sector by 1.45%, suggesting that it is performing better than its peers in the market today.<BR><BR>However, it is important to note that the stock has been experiencing a decline over longer periods, with a year-to-date drop of 40.00% and a one-month decline of 16.73%. The stock is currently trading below its moving averages across various time frames, which typically indicates a bearish trend. Furthermore, there has been a significant decrease in investor participation, with delivery volume falling by 24.8% against the five-day average, which may signal waning interest among investors.<BR><BR>Despite the current rise, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 11.22% over the last five years and a decline in profits by 9.3% over the past year. Institutional investors have also reduced their stakes, indicating a lack of confidence in the stock's future performance. Overall, while the stock is experiencing a short-term rise, the long-term outlook remains concerning due to declining sales growth and reduced institutional interest.

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 25-Mar, Gujarat Themis Biosyn Ltd's stock price is rising to 268.65, reflecting a 1.9% increase. This rise is driven by increased investor participation and recent gains, but the stock faces long-term challenges, including underperformance in its sector and declining profits.

As of 25-Mar, Gujarat Themis Biosyn Ltd's stock price is rising, currently at 268.65, reflecting a change of 5.0 (1.9%) upward. This increase can be attributed to several factors. The stock has shown a consecutive gain over the last two days, rising by 2.3% during this period. Additionally, it opened with a gain of 2.37% today and reached an intraday high of Rs 280.25, which is a 6.3% increase.<BR><BR>Investor participation appears to be increasing, as evidenced by a significant rise in delivery volume, which was 2.34 lacs on 24 March, marking a 327.85% increase compared to the 5-day average delivery volume. This suggests a growing interest among investors, contributing to the stock's upward movement.<BR><BR>However, it is important to note that despite the recent gains, the stock has underperformed its sector by 1.47% today and is trading below its moving averages across various time frames. Furthermore, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 11.22% over the last five years and a decline in profits by 9.3% over the past year. Institutional investor participation has also decreased, which could indicate a lack of confidence among more experienced investors.<BR><BR>In summary, while the stock is currently rising due to recent gains and increased investor participation, it is also facing significant long-term challenges that could impact its future performance.

Which are the latest news on Guj. Themis Bio.?